ValuEngine Lowers Proteostasis Therapeutics (NASDAQ:PTI) to Sell

ValuEngine downgraded shares of Proteostasis Therapeutics (NASDAQ:PTI) from a hold rating to a sell rating in a research report sent to investors on Monday, ValuEngine reports.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald started coverage on Inovio Pharmaceuticals in a research report on Monday, March 25th. They set an overweight rating and a $3.62 price target on the stock. Zacks Investment Research downgraded i3 Verticals from a hold rating to a sell rating in a research report on Friday, March 15th. Finally, Piper Jaffray Companies increased their price target on Beigene to $180.00 and gave the stock an overweight rating in a research report on Thursday, May 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Proteostasis Therapeutics has a consensus rating of Hold and a consensus target price of $9.63.

PTI traded up $0.02 during midday trading on Monday, hitting $1.01. 752,295 shares of the company were exchanged, compared to its average volume of 1,559,526. The business has a 50 day moving average of $1.01. The stock has a market cap of $51.61 million, a price-to-earnings ratio of -0.63 and a beta of -0.66. The company has a quick ratio of 11.29, a current ratio of 11.30 and a debt-to-equity ratio of 0.13. Proteostasis Therapeutics has a 1-year low of $0.91 and a 1-year high of $10.38.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.11. The company had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.80 million. On average, research analysts anticipate that Proteostasis Therapeutics will post -1.45 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of PTI. Great Point Partners LLC purchased a new stake in shares of Proteostasis Therapeutics during the 4th quarter worth about $9,867,000. venBio Select Advisor LLC purchased a new position in Proteostasis Therapeutics in the 4th quarter valued at about $4,212,000. BlackRock Inc. lifted its stake in Proteostasis Therapeutics by 61.1% in the 4th quarter. BlackRock Inc. now owns 2,920,723 shares of the company’s stock valued at $9,464,000 after buying an additional 1,107,731 shares in the last quarter. Hillhouse Capital Advisors Ltd. purchased a new position in Proteostasis Therapeutics in the 4th quarter valued at about $2,806,000. Finally, Macquarie Group Ltd. purchased a new position in Proteostasis Therapeutics in the 4th quarter valued at about $2,430,000. 60.15% of the stock is currently owned by institutional investors and hedge funds.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Recommended Story: What is the Book Value of a Share?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.